Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 4/20 | 0.50 |
| ▸ | ACACA | Q13085 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 7/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973157 | 1.00 | TPH1 (0.52) | TPH1ACACBACACALTA4HSCN9A | |
| SCHEMBL29183302 | 0.96 | ACACB (0.53) | TPH1ACACBLTA4HPPARGPPARA | |
| SCHEMBL2292317 | 0.96 | ACACB (0.53) | TPH1ACACBLTA4HPPARGPPARA | |
| SCHEMBL8255298 | 0.96 | ACACB (0.53) | TPH1ACACBLTA4HPPARGPPARA | |
| Hydrochloric Acid SCHEMBL2292315 | 0.94 | PPARG (0.54) | TPH1ACACBLTA4HPPARGPPARA | |
| Hydrochloric Acid SCHEMBL2292318 | 0.94 | PPARG (0.54) | TPH1ACACBLTA4HPPARGPPARA | |
| SCHEMBL7451018 | 0.90 | SRR (0.54) | TPH1ACACBLTA4HPPARGPPARA | |
| SCHEMBL539325 | 0.90 | SRR (0.54) | TPH1ACACBLTA4HPPARGPPARA | |
| SCHEMBL539324 | 0.90 | SRR (0.54) | TPH1ACACBLTA4HPPARGPPARA | |
| SCHEMBL20240307 | 0.89 | LTA4H (0.53) | ACACBACACALTA4HPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | TPH1 1389/4885ACACB 1320/4885ACACA 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.